The researchers found that the genetic variation acts just like beta-blockers, a class of medications used to take care of chronic heart failure. Research results will be available in the online version of Nature Medication, on 20 April, 2008. In the study, the researchers found that African American heart failure sufferers with the genetic variation experienced a natural protection against death and the need for a center transplant that is the identical to the protection supplied by beta-blocker therapy. The researchers say their discovery increases the accumulating evidence that genetic differences contribute to the method people respond to medications, and really should encourage the use of genetic tests in clinical trials to recognize people who can reap the benefits of therapy tailored with their personal genetic make-up.Park, Ph.D.D., Dana Robbins, B.S., Carsten Russ, Ph.D., Elizabeth M. Ryan, B.S., Jahit Sacarlal, M.D., Ph.D., Brian Sogoloff, B.S., Hermann Sorgho, Ph.D., Marcel Tanner, Ph.D., Thor Theander, M.D., D.Sc., Innocent Valea, Pharm.D., Ph.D., Sarah K. Volkman, Sc.D., Qing Yu, M.Sc., Didier Lapierre, M.D., Bruce W. Birren, Ph.D., Peter B. Gilbert, Ph.D., and Dyann F. Wirth, Ph.D.: Genetic Diversity and Protecting Efficacy of the RTS,S/AS01 Malaria Vaccine Malaria induces substantial morbidity and mortality worldwide1 and has proved to be a problem for vaccine-development efforts. The renewed effort to regulate recently, eliminate, and hopefully eradicate malaria could have a greater likelihood of achievement if a vaccine can be combined with other intervention strategies, such as for example drug-administration insect-vector and campaigns control.2,3 The innovative candidate vaccine for security against Plasmodium falciparum malaria infection, RTS,S/AS01, is a monovalent recombinant protein vaccine that targets a fragment of the circumsporozoite protein parasite antigen.